127 related articles for article (PubMed ID: 12187178)
1. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly.
Hazlet TK; Blough DK
Med Care; 2002 Aug; 40(8):640-9. PubMed ID: 12187178
[TBL] [Abstract][Full Text] [Related]
2. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia.
Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR
CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
[TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
[TBL] [Abstract][Full Text] [Related]
5. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.
Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M
Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490
[TBL] [Abstract][Full Text] [Related]
6. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.
Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR
CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.
Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB
N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794
[TBL] [Abstract][Full Text] [Related]
8. Prescription duration after drug copay changes in older people: methodological aspects.
Schneeweiss S; Maclure M; Soumerai SB
J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050
[TBL] [Abstract][Full Text] [Related]
9. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.
Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB
Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126
[TBL] [Abstract][Full Text] [Related]
10. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
Andrade SE; Gurwitz JH; Fish LS
Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
[TBL] [Abstract][Full Text] [Related]
11. The Impact of reference pricing on prescribing patterns, costs, and health services utilization of proton pump inhibitors: A quasi-experimental study in British Columbia, Canada.
Au SW; Law MR; Cheng L; McGrail K; Harrison M
Health Policy; 2024 Jun; 144():105061. PubMed ID: 38676977
[TBL] [Abstract][Full Text] [Related]
12. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
13. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences.
Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J
Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906
[TBL] [Abstract][Full Text] [Related]
14. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use.
Kalish SC; Bohn RL; Avorn J
Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201
[TBL] [Abstract][Full Text] [Related]
15. Evaluating reference-based pricing: initial findings and prospects.
Narine L; Senathirajah M; Smith T
CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052
[TBL] [Abstract][Full Text] [Related]
16. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.
Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML
Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608
[TBL] [Abstract][Full Text] [Related]
17. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.
Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR
Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135
[TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with prescription drug cost-sharing among poor and elderly persons.
Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L
JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations.
Schneeweiss S; Maclure M; Carleton B; Glynn RJ; Avorn J
BMJ; 2004 Mar; 328(7439):560. PubMed ID: 14982865
[TBL] [Abstract][Full Text] [Related]
20. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia.
Grootendorst P; Stewart D
Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
